Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Brent O'Carrigan, Maria Jose de Miguel Luken, Dionysios Papadatos-Pastos, Jessica Brown, Nina Tunariu, Raquel Perez Lopez, Mahesha Ganegoda, Ruth Riisnaes, Ines Figueiredo, Suzanne Carreira, Brian Hare, Fang Yang, Katherine McDermott et al | ||||||||||||
Title | Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies. | ||||||||||||
|
|||||||||||||
URL | http://abstracts.asco.org/176/AbstView_176_165738.html | ||||||||||||
Abstract Text | J Clin Oncol 34, 2016 (suppl; abstr 2504) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM loss | colorectal cancer | sensitive | Berzosertib | Phase I | Actionable | In a Phase I trial, Berzosertib (VX-970) treatment resulted in complete response for more than 19 months in a colorectal cancer patient harboring ATM loss (J Clin Oncol 34, 2016 (suppl; abstr 2504)). | detail... |